Magazine Article | November 1, 2022

The Model Of A Well-Funded Biotech Startup

Source: Life Science Leader

By J. David Owens

It can hardly be argued that COVID-19 changed the way life sciences business was conducted. A recent McKinsey & Company report indicated double-digit growth in 2019 and 2020 for the biotech industry, in areas including venture capital, partnerships, co-developments, and joint ventures. Initial public offerings grew by triple digits, and venture capital investment grew in biotech by 45%, to a global total of $36.6 billion in 2020.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader